首页 | 本学科首页   官方微博 | 高级检索  
检索        


A novel canine model of partial outlet obstruction secondary to prostatic hypertrophy
Authors:G A Broderick  P A Longhurst  P E Juniewicz  A J Wein  R M Levin
Institution:(1) Division of Urology, 3006 Ravdin Courtyard Building, Hospital of the University of Pennsylvania, 3400 Spruce Street, 19104 Philadelphia, PA, USA;(2) Philadelphia Veterans Administration Medical Center, Philadelphia, Pennsylvania, USA;(3) Sterling Winthrop Pharmaceuticals Research Division, Philadelphia, Pennsylvania, USA
Abstract:Summary Benign prostatic hyperplasia (BPH) is a major medical problem in the United States. The primary medical complication of BPH is progressive obstruction of the urethra and a subsequent in reduction the ability or the bladder to empty efficiently. The urodynamic characteristics associated with BPH include hyperreflexia, increased bladder capacity, increased frequency, decreased flow rate, and increased residual volume. Although there currently are individual animal models of prostate enlargement and animal models of partial outlet obstruction, there is no model of progressive obstruction secondary to prostate enlargement. The primary objective of the current study was to develop a canine model of BPH that would secondarily result in partial urethral obstruction and impaired urodynamics. Our model consists of encapsulating the prostate in a nylon mesh to prevent the growth of the prostate into the peritoneal cavity and then treating the dog with steroids to induce prostate growth and subsequently produce urethral constriction. The results demonstrate that encapsulation of the dog prostate and administration of steroids results in an increase in prostate mass simultaneously with an increase in urethral pressure and in changes in bladder contraction consistent with the presence of partial outlet obstruction. This preliminary study demonstrates that by preventing the outward growth of the steroid-stimulated prostate, urethral obstruction resembling BPH can be produced.This work was supported in part by grants from the Veterans Administration, NIH grants RO-1-DK 26508 and RO-1-DK33559, and the Stterling Winthrop Pharmaceuticals Research Division.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号